nach oben

Erschienen in:

29.03.2021 | review article

The advantages of drug treatment with statins in patients with SARS-CoV-2 infection

verfasst von: Francesco Ferrara, Antonio Vitiello

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 17-18/2021

Einloggen, um Zugang zu erhalten

Summary

On 11 March 2020 the World Health Organization (WHO) declared a status of global pandemic caused by the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease 2019, COVID-19). The pandemic is currently underway, and to date has caused approximately 2.42 million deaths worldwide. The first vaccines have recently been licensed; however, research continues to identify therapeutic agents to prevent serious complications, such as anti-inflammatory, immunomodulatory, anticoagulant or antiviral agents authorized for other therapeutic indications. Epidemiological evidence shows that advanced age and comorbidities, such as diabetes, heart disease, and dyslipidemia may represent COVID-19 risk factors. In particular, in patients with hypercholesterolemia treated with statins, it is recommended that treatment should not be discontinued if COVID-19 infection occurs. The pleiotropic effects of statins are well known. In this brief review, we propose that the use of statins can potentially protect against SARS-CoV-2-induced tissue damage and improve lung function in COVID-19 patients through several pleiotropic effects. Pleiotropic effects of statins that may be a significant benefit in patients with hypercholesterolemia treated with statins and COVID-19 positive. Recent evidence shows promising results.

Vorheriger Artikel COVID-19 and air pollution in Vienna—a time series approach

Nächster Artikel Alterations of the male and female reproductive systems induced by COVID-19

World health organization (WHO). Situation Reports September 2020.. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. Accessed 10 February 2021.

Wu Y. Compensation of ACE2 function for possible clinical management of 2019—nCoV-Induced acute lung injury. Virol Sin. 2020; https://doi.org/10.1007/s12250-020-00205-6.CrossRefPubMedPubMedCentral

Guoping L, Xiang H, Lei Z, Qin R, Junyi W, Anying X, et al. Assessing ACE2 expression patterns in lung tissues in the pathogenesis of COVID-19. J Autoimmun. 2020;13:102463. https://doi.org/10.1016/j.jaut.2020.102463.CrossRef

Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel Coronavirus-infected pneumonia. N Engl J Med. 2020;382:1199.PubMedPubMedCentralCrossRef

Vitiello A, Ferrara F. Correlation between renin-angiotensin system and severe acute respiratory syndrome Coronavirus 2 infection: what do we know? Eur J Pharmacol. 2020;883:173373. https://doi.org/10.1016/j.ejphar.2020.173373.CrossRefPubMedPubMedCentral

Chen N, Zhou M, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–13.PubMedPubMedCentralCrossRef

Ferrara F, Porta R, D’Aiuto V, Vitiello A. Remdesivir and COVID-19. Ir J Med Sci. 2020;17:1–2. https://doi.org/10.1007/s11845-020-02401-5.CrossRef

Vitiello A, Ferrara F. Therapeutic strategies for SARS-coV‑2 acting on ACE‑2. Eur J Pharm Sci. 2021;156:105579. https://doi.org/10.1016/j.ejps.2020.105579.CrossRefPubMed

Vitiello A, La Porta R, Ferrara F. Sacubitril, valsartan and SARS-CoV‑2. BMJ Evid Based Med. 2020; https://doi.org/10.1136/bmjebm-2020-111497.CrossRefPubMed

10.

Vitiello A, Ferrara F. Remdesivir versus ritonavir/lopinavir in COVID-19 patients. Ir J Med Sci. 2020; https://doi.org/10.1007/s11845-020-02440-y.CrossRefPubMedPubMedCentral

11.

Vitiello A, La Porta R, Ferrara F. Scientific hypothesis and rational pharmacological for the use of sacubitril/valsartan in cardiac damage caused by COVID-19. Med Hypotheses. 2021; https://doi.org/10.1016/j.mehy.2021.110486.CrossRefPubMedPubMedCentral

12.

Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of Coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708.PubMedCrossRef

13.

Struyf T, Deeks JJ, Dinnes J, et al. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease. Cochrane Database Syst Rev. 2020; https://doi.org/10.1002/14651858.CD013665.CrossRefPubMedPubMedCentral

14.

Chung TW, Sridhar S, Zhang AJ, et al. Olfactory dysfunction in Coronavirus disease 2019 patients: observational cohort study and systematic review. Open Forum Infect Dis. 2020;7:ofaa199.PubMedPubMedCentralCrossRef

15.

Tong JY, Wong A, Zhu D, et al. The prevalence of olfactory and gustatory dysfunction in COVID-19 patients: a systematic review and meta-analysis. Otolaryngol Head Neck Surg. 2020;163:3.PubMedCrossRef

16.

Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;323:1061.PubMedPubMedCentralCrossRef

17.

Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol. 2020;34:e212.PubMedCrossRef

18.

Arentz M, Yim E, Klaff L, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington state. JAMA. 2020;323:1612.PubMedPubMedCentralCrossRef

19.

Xie Y, Wang X, Yang P, Zhang S. COVID-19 complicated by acute pulmonary embolism. Radiol Cardiothorac Imaging. 2020;2(2):e200067. https://doi.org/10.1148/ryct.2020200067.CrossRefPubMedPubMedCentral

20.

Fan Z, Chen L, Li J, Tian C, Zhang Y, Huang S, et al. Clinical features of COVID-19 related liver damage. medRxiv. 2020. https://doi.org/10.1101/2020.02.26.20026971.CrossRef

21.

Chai X, Hu L, Zhang Y, Han W, Lu Z, Ke A. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. BioRxiv. 2020; https://doi.org/10.1101/2020.02.03.931766.CrossRef

22.

Vitiello A, Ferrara F, Pelliccia C, Granata G, La Porta R. Cytokine storm and colchicine potential role in fighting SARS-CoV‑2 pneumonia. Ital J Med. 2020;14(2):88–94. https://doi.org/10.4081/itjm.2020.1284.CrossRef

23.

Yang Z, Xu M, Yi JQ, Jia WD. Clinical characteristics and mechanism of liver damage in patients with severe acute respiratory syndrome. Hepatobiliary Pancreat Dis Int. 2005;4:60–3.PubMed

24.

Ferrara F, Granata G, Pelliccia C, et al. The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV‑2. Eur J Clin Pharmacol. 2020; https://doi.org/10.1007/s00228-020-02947-4.CrossRefPubMedPubMedCentral

25.

American Lung Association. Lung Health & COVID-19.. https://www.lung.org/lung-health-diseases/lung-disease-lookup/covid-19/faq. Accessed 3 Apr 2020.

26.

Vitiello A, Pelliccia C, Ferrara F. Drugs acting on the renin-angiotensin system and SARS-CoV‑2. Drug Discov Today. 2021;21:1359–6446. https://doi.org/10.1016/j.drudis.2021.01.010.CrossRef

27.

Gupta R, et al. Clinical considerations for patients with diabetes in times of COVID-19 epidemic. Diabetes Metab Syndr Clin Res Rev. 2020; https://doi.org/10.1016/j.dsx.2020.03.002.CrossRef

28.

Vitiello A, Ferrara F. Pharmacological agents to therapeutic treatment of cardiac injury caused by Covid-19. Proc Natl Sci Counc Repub China B. 2020; https://doi.org/10.1016/j.lfs.2020.118510.CrossRef

29.

LaRosa JC, He J, Vupputuri S. Effects of statins on risk of coronary artery disease: a meta-analysis of randomized controlled trials. JAMA. 1999;282:2340–6.PubMedCrossRef

30.

Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systemic review and meta-analysis. BMJ. 2003;326:1423.PubMedPubMedCentralCrossRef

31.

Takemoto M, Liao JK. Pleiotropic effects of 3‑hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001;21:1712–9.PubMedCrossRef

32.

Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001–9.PubMedCrossRef

33.

Group TL-TIwPi. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349–57.CrossRef

34.

Noma K, Oyama N, Liao JK. Physiological role of ROCKs in the cardiovascular system. Am J Physiol, Cell Physiol. 2006;290(16469861):C661–C8.CrossRef

35.

Kataoka C, Egashira K, Inoue S, Takemoto M, Ni W, Koyanagi M, et al. Important role of Rho-kinase in the pathogenesis of cardiovascular inflammation and remodeling induced by long-term blockade of nitric oxide synthesis in rats. Hypertension. 2002;39:245–50.PubMedCrossRef

36.

Higashi M, Shimokawa H, Hattori T, Hiroki J, Mukai Y, Morikawa K, et al. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circ Res. 2003;93:767–75.PubMedCrossRef

37.

Do EZ, Fukumoto Y, Sugimura K, et al. Rho-kinase activation in patients with heart failure. Circ J. 2013;77:2542–50.CrossRef

38.

Ohnaka K, Shimoda S, Nawata H, Shimokawa H, Kaibuchi K, Iwamoto Y, et al. Pitavastatin enhanced BMP‑2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts. Biochem Biophys Res Commun. 2001;287:337–42.PubMedCrossRef

39.

Ma MM, Li SY, Wang M, Guan YY. Simvastatin attenuated cerebrovascular cell proliferation in the development of hypertension through Rho/Rho-kinase pathway. J Cardiovasc Pharmacol. 2012;59:576–82.PubMedCrossRef

40.

Satoh M, Ogita H, Takeshita K, Mukai Y, Kwiatkowski DJ, Liao JK. Requirement of Rac1 in the development of cardiac hypertrophy. Proc Natl Acad Sci U S A. 2006;103:7432–7.PubMedPubMedCentralCrossRef

41.

Tanaka S, Fukumoto Y, Nochioka K, Minami T, Kudo S, Shiba N, et al. Statins exert the pleiotropic effects through small GTP-binding protein dissociation stimulator upregulation with a resultant Rac1 degradation. Arterioscler Thromb Vasc Biol. 2013;33:1591–600.PubMedCrossRef

42.

Jones SP, Teshima Y, Akao M, Marban E. Simvastatin attenuates oxidant-induced mitochondrial dysfunction in cardiac myocytes. Circ Res. 2003;93:697–9.PubMedCrossRef

43.

Node K, Fujita M, Kitakaze M, Hori M, Liao JK. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation. 2003;108:839–43.PubMedPubMedCentralCrossRef

44.

Buber J, Goldenberg I, Moss AJ, Wang PJ, McNitt S, Hall WJ et al. Reduction in Life-Threatening Ventricular Tachyarrhythmias in Statin-Treated Patients With Nonischemic Cardiomyopathy Enrolled in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy). J Am Coll Cardiol. 2012;60:749–55.PubMedCrossRef

45.

Muhlhauser U, Zolk O, Rau T, Munzel F, Wieland T, Eschenhagen T. Atorvastatin desensitizes beta-adrenergic signaling in cardiac myocytes via reduced isoprenylation of G‑protein gamma-subunits. FASEB J. 2006;20:785–7.PubMedCrossRef

46.

Ridker PM, et al. Measurement of C‑reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344:1959–65.PubMedCrossRef

47.

Taubes G. Does inflammation cut to the heart of the matter? Science. 2002;296:242–5.PubMedCrossRef

48.

Diomede L, et al. In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler Thromb Vasc Biol. 2001;21:1327–32.PubMedCrossRef

49.

Stalker TJ, et al. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid. Br J Pharmacol. 2001;133:406–12.PubMedPubMedCentralCrossRef

50.

Liu L, et al. Integrin-dependent leukocyte adhesion involves geranylgeranylated protein(s). J Biol Chem. 1999;274:33334–40.PubMedCrossRef

51.

Takeuchi S, et al. Cerivastatin suppresses lipopolysaccharide-induced ICAM‑1 expression through inhibition of the rho GTPase in BAEC. Biochem Biophys Res Commun. 2000;269:97–102.PubMedCrossRef

52.

Inoue I, et al. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: Reduction of mRNAlevels for interleukin-1β, interleukin‑6, cyclooxygenase‑2, and p22phlox by regulation of peroxisome proliferator-activated receptor α(PPARα) in primary endothelial cells. Life Sci. 2000;67:863–76.PubMedCrossRef

53.

Ikeda U, Shimada K. Statins and monocytes. Lancet. 1999;353:2070.PubMedCrossRef

54.

Grip O, et al. Atorvastatin activates PPAR-γand attenuates the inflammatory response in human monocytes. Inflamm Res. 2002;51:58–62.PubMedCrossRef

55.

Zelvyte I, et al. Modulation of inflammatory mediators and PPARγand NFκB expression by pravastatin in response to lipoproteins in human monocytes in vitro. Pharmacol Res. 2002;45:147–54.PubMedCrossRef

56.

Laufs U, et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998;97:1129–35.PubMedCrossRef

57.

Ortego M, et al. Atorvastatin reduces NF-κB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis. 1999;147:253–61.PubMedCrossRef

58.

Vitiello A, La Porta R, D’Aiuto V, Ferrara F. Pharmacological approach for the reduction of inflammatory and prothrombotic hyperactive state in COVID-19 positive patients by acting on complement cascade. Hum Immunol. 2021; https://doi.org/10.1016/j.humimm.2021.01.007.CrossRefPubMedPubMedCentral

59.

Vitiello V, Ferrara F. Colchicine and SARS-CoV-2: management of the hyperinflammatory state. Respir Med. 2021; https://doi.org/10.1016/j.rmed.2021.106322.CrossRefPubMedPubMedCentral

60.

Campioni M, Severino A, Manente L, De Luca A, La Porta R, Vitiello A, et al. Identification of protein-protein interactions of human HtrA1. Front Biosci. 2011;3:1493–9. https://doi.org/10.2741/e350.CrossRef

61.

Ferrara F, Vitiello A. Efficacy of synthetic glucocorticoids in COVID-19 endothelites. Naunyn Schmiedebergs Arch Pharmacol. 2021; https://doi.org/10.1007/s00210-021-02049-7.CrossRefPubMedPubMedCentral

62.

Verpaalen B, Neyts J, Delang L. Are statins a viable option for the treatment of infections with the hepatitis C virus? Antiviral Res. 2014;105:92–9. https://doi.org/10.1016/j.antiviral.2014.02.020.CrossRefPubMed

63.

Zhu Q, Han Q, Liu Z. Potenzial role for statins in the treatment of chronic HCV infection. Future Virol. 2013;8:727–9. https://doi.org/10.2217/fvl.13.70.CrossRef

64.

Ikeda M, Abe K, Yamada M, Dansako H, Naka K, Kato N. Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology. 2006;44:117–25. https://doi.org/10.1002/hep.21232.CrossRefPubMed

65.

Trebicka J, Hennenberg M, Laleman W. et alAtorvastatin lowers portal pressure in cirrhotic rats byinhibition of RhoA/Rho-kinase and activation ofendothelial nitric oxide synthase. Hepatology. 2007;46:242–5.PubMedCrossRef

66.

Marrone G, Maeso-Diaz R, Garcia-Cardena G, et al. KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanismsof statins. Gut. 2014; https://doi.org/10.1136/gutjnl-2014-308338.CrossRefPubMed

67.

Watts KL, Sampson EM, Schultz GS, et al. Simvastatin inhibits growth factor expression and modulates profibrogenic markers in lung fibroblasts. Am J Respir Cell Mol Biol. 2005;32:290–300.PubMedCrossRef

68.

Nadrous HF, Ryu JH, Douglas WW, et al. Impact of angiotensin-converting enzyme inhibitors and statins on survival in idiopathic pulmonary fibrosis. Chest. 2004;126:438–46.PubMedCrossRef

69.

Meisel SR, Xu XP, Edgington TS, et al. Dose-dependent modulation of tissue factor protein andprocoagulantactivity in humanmonocyte-derived macrophagesbyoxidizedlowdensitylipoprotein. J Atheroscler Thromb. 2011;18(7):596–603.PubMedCrossRef

70.

Owens AP 3rd, Mackman N. The antithrombotic effects of statins. Annu Rev Med. 2014;65:433–45. https://doi.org/10.1146/annurev-med-051812-145304.CrossRefPubMed

71.

Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45:89–118. https://doi.org/10.1146/annurev.pharmtox.45.120403.095748.CrossRefPubMedPubMedCentral

72.

Yildirim M, Kayalar O, Atahan E, Oztay F. Anti-fibrotic effect of atorvastatin on the lung fibroblasts and myofibroblasts. Eur Respir J. 2018;52(Suppl 62):PA991. https://doi.org/10.1183/13993003.congress.CrossRef

73.

Ferrara F, Vitiello A. Potenzial pharmacological approach in the regulation of ACE‑2 and DPP-IV in diabetic COVID-19 patient. Ital J Med. 2020; https://doi.org/10.4081/itjm.2020.1435.CrossRef

74.

Zhang XJ, Qin JJ, Cheng X, et al. In-hospital use of Statins is associated with a reduced risk of mortality among individuals with COVID-19. Cell Metab. 2020;32(2):176–187.e4. https://doi.org/10.1016/j.cmet.2020.06.015.CrossRefPubMedPubMedCentral

75.

Rodriguez-Nava G, Trelles-Garcia DP, Yanez-Bello MA, Chung CW, Trelles-Garcia VP, Friedman HJ. Atorvastatin associated with decreased hazard for death in COVID-19 patients admitted to an ICU: a retrospective cohort study. Crit Care. 2020;24:429.PubMedPubMedCentralCrossRef

76.

Siang Kow C, Syed Shahzad H. meta-analysis of effect of Statins in patients with COVID-19. Am J Cardiol. 2020; https://doi.org/10.1016/j.amjcard.2020.08.004.CrossRef

77.

Daniels LB, Sitapati AM, Zhang J, Zou J, Bui QM, Ren J, Longhurst CA, Criqui MH, Messer K. Relation of Statin Use Prior to Admission to Severity and Recovery Among COVID-19 Inpatients. Am J Cardiol. 2020;136:149–155. https://doi.org/10.1016/j.amjcard.2020.09.012.CrossRefPubMedPubMedCentral

78.

Tan WYT, Young BE, Lye DC, et al. Statin use is associated with lower disease severity in COVID-19 infection. Sci Rep. 2020;10:17458. https://doi.org/10.1038/s41598-020-74492-0.CrossRefPubMedPubMedCentral

79.

Vitiello A, La Porta R, Ferrara F. Correlation between the use of statins and COVID-19: what do we know? BMJ Evid Based Med. 2020; https://doi.org/10.1136/bmjebm-2020-111589.CrossRefPubMed

80.

Turner RM, Pirmohamed M. Statin-related myotoxicity: a comprehensive review of pharmacokinetic, pharmacogenomics and muscle components. J Clin Med. 2020; https://doi.org/10.3390/jcm9010022.CrossRefPubMedPubMedCentral

81.

Liverpool COVID-19 drug interactions.. http://www.covid19-druginteractions.org/. Accessed 20 Mar 2020.

82.

Ferrara F. Antirheumatic in SARS-CoV-2: benefit or risk? Ital J Med. 2020;14(2):114–5. https://doi.org/10.4081/itjm.2020.1290.CrossRef

83.

Ferrara F, Porta R, Santilli P, D’Aiuto V, Vitiello A. Are multiple sclerosis therapies safe in severe acute respiratory syndrome coronavirus 2 times? Indian J Pharmacol. 2020;52(5):441–2. https://doi.org/10.4103/ijp.IJP_417_20.CrossRefPubMedPubMedCentral

84.

Lombardi N, Crescioli G, Bettiol A, Marconi E, Vitiello A, Bonaiuti R, et al. Characterization of serious adverse drug reactions as cause of emergency department visit in children: a 5-years active pharmacovigilance study. BMC Pharmacol Toxicol. 2018;19(1):16. https://doi.org/10.1186/s40360-018-0207-4.CrossRefPubMedPubMedCentral

85.

Vitiello R, Ferrara F, La Porta R. Remdesivir and COVID-19 infection, therapeutic benefitsor unnecessary risks? Ir J Med Sci. 2020; https://doi.org/10.1007/s11845-020-02482-2.CrossRefPubMedPubMedCentral

86.

Vitiello A, La Porta R, D’Aiuto V, Ferrara F. The risks of liver injury in COVID-19 patients and pharmacological management to reduce or prevent the damage induced. Egypt Liver J. 2021;11:11. https://doi.org/10.1186/s43066-021-00082-y.CrossRefPubMed

Titel: The advantages of drug treatment with statins in patients with SARS-CoV-2 infection
verfasst von: Francesco Ferrara
Antonio Vitiello
Publikationsdatum: 29.03.2021
Verlag: Springer Vienna
Erschienen in: Wiener klinische Wochenschrift / Ausgabe 17-18/2021
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI: https://doi.org/10.1007/s00508-021-01845-8

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 17-18/2021

Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2

Alterations of the male and female reproductive systems induced by COVID-19

MUW researcher of the month

SARS-CoV-2 screening in cancer outpatients during the second wave of the COVID-19 pandemic

COVID-19-associated myoclonus in a series of five critically ill patients

COVID-19 serology in nephrology healthcare workers